Bioactive ingredients are more complex and sensitive than chemically derived alternatives, requiring stabilisation in solution with specific excipients to preserve their full effectiveness.
We offer a range of high-quality pharmaceutical grade polysorbates to ensure the most stable formulations.
MONTANOXâ„¢ 20 HPB has been specifically developed to meet the needs of biopharmaceutical formulators, offering high purity and stricter specifications for fatty acid distribution. These features minimise the risk of active ingredient degradation, while improving bioavailability, stability, and formulation protection. The MONTANOXâ„¢ 20 HPB polysorbate has a controlled fatty acid (FA) distribution: fewer long FA chain (palmitric, stearic and myristic acid) and high content of main FA (lauric acid), which is compatible with the complex biological APIs in formulation.
Due to its well-balanced composition, MONTANOXâ„¢ 20 HPB polysorbate helps to:
MONTANOXâ„¢ 20 HPB can be combined with MONTANEâ„¢ PPI products to obtain high-stability emulsions.
MONTANOXâ„¢ 20 HPB complies with good manufacturing practices (GMP II) and current Pharmacopeias in force (EP, USP-NF, JP, CHP)
The recommended level of use is 0.01-0.1%.
Lene Aarøe Nissen
Head of Nordic Sales
+45 22 70 10 02
lan@alsiano.com